Please use this identifier to cite or link to this item:
Type: Artigo
Title: Combinatorial effect of abiraterone acetate and NVP-BEZ235 on prostate tumor progression in rats
Author: Gonçalves, Bianca Facchim
Campos, Silvana Gisele Pegorin de
Fávaro, Wagner José
Brandt, Joyce Zalotti
Pinho, Cristiane Figueiredo
Justulin, Luis Antônio
Taboga, Sebastião Roberto
Scarano, Wellerson Rodrigo
Abstract: Use of drug combinations that target different pathways involved in the development and progression of prostate cancer (PCa) has emerged as an alternative to overcome the resistance caused by drug monotherapies. The antiandrogen abiraterone acetate and the PI3K/Akt inhibitor NVP-BEZ235 (BEZ235) may be suitable options for the prevention of drug resistance and the inhibition of PCa progression. The aim of the present study was to evaluate whether abiraterone acetate and BEZ235 achieve superior therapeutic effects to either drug administered as monotherapy, in the early stages of PCa in an androgen-dependent system. Our study showed that each drug might impair tumor growth by reducing proliferation and increasing cell death when administered as monotherapy. However, tumor growth continued to progress with each drug monotherapy and some important side effects were related to BEZ. Conversely, when used in combination, the drugs impaired the inflammatory response, decreased hyperplastic lesions, and blocked tumor progression from premalignant to a malignant stage. Our data showed that the strategy to block the androgenic and PI3K/AKT/mTOR pathway is an effective therapeutic option and should be investigated including distinct PI3K pathway inhibitors
Subject: Acetato de abiraterona
Inibidores de fosfoinositídeo-3 quinase
Próstata - Câncer
Country: Estados Unidos
Editor: Springer
Rights: Fechado
Identifier DOI: 10.1007/s12672-018-0323-z
Date Issue: 2018
Appears in Collections:IB - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
29363091.pdf2.1 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.